Bullish & Foolish
Full ERNA fundamentals All 466 on the Survival Watch

ERNAErnexa Therapeutics Inc.

Is Ernexa Therapeutics struggling financially?

Yes, by its own account. Ernexa Therapeutics told the SEC on 11 May 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$7.9M
Source filing
DEF 14A 11 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 7months

    If the burn speeds up

    Empty by Jan 2027

  • 10months

    If it eases off

    Empty by Apr 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$5.0M

÷

Cash burned over the last 12 months

$7.1M

What Ernexa Therapeutics told the SEC

…qualified or modified as to uncertainty, audit scope, or accounting principles, except that, the reports included an explanatory paragraph describing that substantial doubt was raised as to the Company’s ability to continue as a going concern. During the two years ended December 31, 2024 and the subsequent interim period through June 30, 2025, there were no (i) disagreements (as defined in Item 304(a)(1)(iv) of Regulation…

Ernexa Therapeutics Inc., Form DEF 14A, filed 11 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 69% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt